search

Foghorn Therapeutics Inc (FHTX)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
Oct 29, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

Pomerantz LLP is investigating potential securities fraud claims against Foghorn Therapeutics Inc. (FHTX) after the company announced it would not advance its FHD-909 clinical program and other collaboration activities with Lilly, leading to a 40% workforce reduction. This news caused Foghorn's stock price to fall by over 30%. The law firm is advising investors who may have been affected to contact them regarding joining a class action.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Bearish